United Therapeutics: Hypertension, Pulmonary trials

The registry lists 30 Hypertension, Pulmonary studies with United Therapeutics as lead sponsor. 2 are open to participants now and 17 have results posted.

Phase 1 2Phase 2 7Phase 3 16Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingNCT06388421
• A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionEnrolling by invitationNCT03683186Phase 3
• Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsTerminatedNCT04084678Phase 3Results posted
• Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)TerminatedNCT03794583Phase 3Results posted
• A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)TerminatedNCT03496623Phase 3Results posted
• Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEFTerminatedNCT03043651Phase 3Results posted
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection FractionTerminatedNCT03037580Phase 3Results posted
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFETerminatedNCT02633293Phase 2/3Results posted
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFECompletedNCT02630316Phase 2/3Results posted
• Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the NewbornTerminatedNCT02261883Phase 2Results posted
• A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary HypertensionCompletedNCT01104870Phase 2Results posted
• A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary HypertensionCompletedNCT01028651Results posted
• Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial HypertensionCompletedNCT00887978Phase 3Results posted
• Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary FibrosisTerminatedNCT00703339Phase 2Results posted
• Rapid Switch From Flolan to Remodulin in the Outpatient ClinicTerminatedNCT00643604Phase 4Results posted
• Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to RemodulinCompletedNCT00373360Phase 4Results posted
• FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325442Phase 3Results posted
• FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT00325403Phase 3Results posted
• Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)CompletedNCT00147199Phase 3Results posted
• Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier DetectionCompletedNCT05776225
• A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsCompletedNCT03626688Phase 3
• Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)WithdrawnNCT03055234Phase 3
• Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPDWithdrawnNCT03012646Phase 2
• Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary FibrosisWithdrawnNCT02603068Phase 2
• Effect of Esomeprazole on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963027Phase 1
• Effect of Food on the Pharmacokinetics of Oral TreprostinilCompletedNCT00963001Phase 1
• FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)WithdrawnNCT00760916Phase 3
• Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment SatisfactionTerminatedNCT00458042Phase 4
• A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial HypertensionCompletedNCT00058929Phase 4
• Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary HypertensionCompletedNCT00004497Phase 3